Hyaline membrane disease

Hyaline Membrane Disease (HMD), also known as Respiratory Distress Syndrome (RDS) of the newborn, is a condition primarily affecting premature infants. This disease is characterized by the insufficient production of surfactant, a lung substance that prevents the collapse of alveoli (tiny air sacs in the lungs) during exhalation. The term "hyaline" refers to the glassy appearance of the membranes that form within the infants' lungs. This article provides a comprehensive overview of Hyaline Membrane Disease, including its causes, symptoms, diagnosis, treatment, and prognosis.

Causes

Hyaline Membrane Disease is most commonly caused by a deficiency of surfactant in the lungs of premature infants. Surfactant is a complex system of lipids and proteins that reduces surface tension within the alveoli, preventing their collapse. The production of surfactant begins late in fetal life, and therefore, infants born prematurely (generally before 37 weeks of gestation) are at a higher risk of developing HMD due to insufficient surfactant levels.

Symptoms

The primary symptom of Hyaline Membrane Disease is significant respiratory distress shortly after birth, which may include:

• Rapid, shallow breathing
• Grunting sounds with exhalation
• Nasal flaring
• Retractions (the chest appears to sink in below the ribs with each breath)
• Cyanosis (a bluish color of the skin, lips, and nails due to lack of oxygen)

Diagnosis

Diagnosis of Hyaline Membrane Disease is based on clinical signs and symptoms, as well as diagnostic tests, including:

• Chest X-ray: Reveals a characteristic "ground glass" appearance of the lungs, indicative of widespread atelectasis (collapse of lung tissue).
• Blood gas analysis: Shows decreased oxygen and increased carbon dioxide levels.
• Preterm birth: The condition is strongly associated with premature delivery.

Treatment

Treatment of Hyaline Membrane Disease focuses on supporting the infant's breathing and increasing surfactant levels in the lungs. Treatment options include:

• Surfactant Replacement Therapy: Direct administration of surfactant into the infant's lungs through a breathing tube.
• Mechanical ventilation: Use of a machine to help the infant breathe while their lungs mature.
• Continuous Positive Airway Pressure (CPAP): Delivers air to the lungs under slight pressure to keep the airways open.
• Supplemental oxygen: Provided to increase the oxygen levels in the blood.

Prognosis

With advances in neonatal care, the prognosis for infants with Hyaline Membrane Disease has significantly improved. Early diagnosis and treatment are crucial for a positive outcome. Most infants who receive prompt treatment for HMD recover fully, although some may experience long-term respiratory problems, such as Bronchopulmonary Dysplasia (BPD).

Prevention

Prevention of Hyaline Membrane Disease involves measures to prevent premature birth when possible and the administration of corticosteroids to pregnant women at risk of preterm delivery. Corticosteroids can accelerate fetal lung maturation and surfactant production, reducing the risk of HMD in the newborn.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian